Evaluation of Hydroxy Choloroquine on Generalized Vitiligo Vulgaris
Phase 2
- Conditions
- Generalized Vitiligo vulgaris.Vitiligo
- Registration Number
- IRCT20201212049690N1
- Lead Sponsor
- Islamic Azad University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Involvement of at least 10% of body surface
At least one month has passed since the last treatment for the patient
Not receiving any other treatment
Not taking other drugs at the same time with immunomodulatory and immunosuppressive effects
Over 7 years old
Weight over 35 kg
Do not take drugs that interfere with hydroxychloroquine, such as Image result for artemether and Dapsone and Lumfanterin
Exclusion Criteria
Glucose-6-phosphate dehydrogenase deficiency
Retinopathy
Acute gastrointestinal disorders
Myasthenia gravis
Psoriasis
Renal failure
Sensitivity to antimalarial compounds
Hepatic failure
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Score in Vasi Score. Timepoint: Before starting treatment, one-two-three month after start using drug. Method of measurement: Vasi Score.
- Secondary Outcome Measures
Name Time Method